نتائج البحث - Sang‐We Kim

تنقيح النتائج
  1. 1
    Hematopoietic-specific β1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2

    Hematopoietic-specific β1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2 حسب Patrick Lécine, Joseph E. Italiano, Sang‐We Kim, Jean‐Luc Villeval, Ramesh A. Shivdasani

    منشور في 2000
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

    ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences حسب İrfan Çiçin, Claudio Martín, Carolina Kawamura Haddad, Sang‐We Kim, Alexey Smolin, Arif Abdillah, Xue Yang

    منشور في 2022
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis

    Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis حسب Harald Schulze, Manav Korpal, Jonathan Hurov, Sang-We Kim, Jinghang Zhang, Lewis C. Cantley, Thomas Graf, Ramesh A. Shivdasani

    منشور في 2006
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor

    Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor حسب Mi-Woo Lee, Chul-Won Seo, Sang‐We Kim, Hwa-Jeong Yang, Hae‐Woong Lee, Jee‐Ho Choi, Kee‐Chan Moon, Jai‐Kyoung Koh

    منشور في 2003
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

    Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy حسب Dae Ho Lee, Keunchil Park, Joo Hang Kim, Jong Seok Lee, Sang Won Shin, Jin Hyoung Kang, Myung‐Ju Ahn, Jin Seok Ahn, Cheolwon Suh, Sang-We Kim

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung

    [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung حسب Hee-Jung Sohn, You-Jung Yang, Jin‐Sook Ryu, Seung Jun Oh, Ki Chun Im, Dae Hyuk Moon, Dae Ho Lee, Cheolwon Suh, Jung‐Shin Lee, Sang‐We Kim

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

    Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer حسب Wonjun Ji, Chang‐Min Choi, Jin Kyung Rho, Se Jin Jang, Young Soo Park, Sung‐Min Chun, Woo Sung Kim, Jung‐Shin Lee, Sang‐We Kim, Dae Ho Lee, Jae Cheol Lee

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

    First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non... حسب Keunchil Park, Chong‐Jen Yu, Sang-We Kim, Meng-Chih Lin, Virote Sriuranpong, Chun-Ming Tsai, Jong-Seok Lee, Jin Hyoung Kang, K.C. Chan, Pablo Ernesto Pérez, Peter Button, Myung‐Ju Ahn, Tony Mok

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer حسب Ben Creelan, Tammie C. Yeh, Sang-We Kim, Naoyuki Nogami, Dong‐Wan Kim, Laura Q.M. Chow, Shintaro Kanda, Rosemary Taylor, Weifeng Tang, Mei Tang, Helen K. Angell, Martine P. Roudier, Marcelo Marotti, Don L. Gibbons

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

    Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations حسب Alessandra Bearz, Jean‐François Martini, Jacek Jassem, Sang‐We Kim, Gee‐Chen Chang, Alice T. Shaw, D A Shepard, E. Dall’O’, Anna Polli, Holger Thurm, Gérard Zalcman, M.R. García Campelo, Konstantin Penkov, Hidetoshi Hayashi, Benjamin Solomon

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report

    CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report حسب Dong‐Wan Kim, Sang‐We Kim, D. Ross Camidge, Catherine A. Shu, Kristen A. Marrone, Xiuning Le, Collin M. Blakely, Keunchil Park, Gee‐Chen Chang, Sandip Pravin Patel, Gozde Kar, Zachary A. Cooper, Ramin Samadani, Michael Pluta, Rakesh Kumar, Suresh S. Ramalingam

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

    Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer حسب Enriqueta Felip, Fabrice Barlési, Benjamin Besse, Quincy Chu, Leena Gandhi, Sang‐We Kim, Enric Carcereny, Lecia V. Sequist, Paal Brunsvig, C. Chouaïd, Egbert F. Smit, Harry J.M. Groen, Dong‐Wan Kim, Keunchil Park, Emin Avşar, Sebastian Szpakowski, Mikhail Akimov, Edward B. Garon

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

    Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study حسب James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim, Jong Seok Lee, Byoung Chul Cho, Jin-Seok Ahn, Dae H. Lee, Tae Min Kim, Jonathan W. Goldman, Ronald B. Natale, Andy Brown, Barbara Collins, Juliann Chmielecki, Karthick Vishwanathan, Ariadna Mendoza‐Naranjo, Myung‐Ju Ahn

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer حسب Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang‐We Kim, James Chih‐Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, M.R. García Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao Mark Lin, Minal Mehta, Pasi A. Jänne

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

    Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201 حسب Byoung Chul Cho, Ji‐Youn Han, Ki Hyeong Lee, Yun‐Gyoo Lee, Dong‐Wan Kim, Young Joo Min, Sang‐We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong‐Won Lee, Sung Sook Lee, NaMi Lee, Jang Young Wang, Hyejoo Park, Myung‐Ju Ahn

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

    Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial حسب Benjamin Solomon, Ibiayi Dagogo‐Jack, Se-Hoon Lee, Michael Boyer, Suresh S. Ramalingam, Enric Carcereny, Enriqueta Felip, Ji‐Youn Han, Toyoaki Hida, Brett Hughes, Sang‐We Kim, Makoto Nishio, Takashi Seto, Tatsuro Okamoto, Xiaoxi Zhang, Jean‐François Martini, Erjian Wang, Steven De Beukelaer, Todd M. Bauer

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)

    Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01) حسب Jong‐Mu Sun, Ki Hyeong Lee, Sang‐we Kim, Dae Ho Lee, Young Joo Min, Hwan‐Jung Yun, Hoon Kyo Kim, Hong Song, Yeul Hong Kim, Bong‐Seog Kim, In Gyu Hwang, Keehyun Lee, Sook Jung Jo, Won Jae Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

    ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearr... حسب Byoung Chul Cho, Dong‐Wan Kim, Alessandra Bearz, Scott A. Laurie, Mark J. McKeage, Gloria Borra, Keunchil Park, Sang-We Kim, Marwan Ghosn, Andrea Ardizzoni, Evaristo Maiello, Alastair Greystoke, Richard Yu, Karen A. Osborne, Wen Gu, Jeffrey W. Scott, Vanessa Q. Passos, Yvonne Lau, Anna Wrona

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study

    Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study حسب Matthew Krebs, Jean‐Pierre Delord, T.R. Jeffry Evans, Maja J.A. de Jonge, Sang‐We Kim, Marie Meurer, Sophie Postel‐Vinay, Jong Seok Lee, Helen K. Angell, Vidalba Rocher-Ros, Kassondra Meyer, Mei-Lin Ah-See, Pia Herbolsheimer, Zhongwu Lai, Ana Nunes, Susan M. Domchek

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

    Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON) حسب Edward B. Garon, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Sang‐We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng‐Ta Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, Nenad Medić, Helen Mann, Xiaojin Shi, Solange Peters, Tony Mok, Melissa L. Johnson

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: